{"product_id":"tandemdiabetes-bcg-matrix","title":"Tandem Diabetes Care Boston Consulting Group Matrix","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored analysis for the featured company’s product portfolio\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eClean, distraction-free view optimized for C-level presentation to clearly show the current state of the business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eTandem Diabetes Care BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Tandem Diabetes Care BCG Matrix preview is identical to the document you'll get. This isn't a demo; it's the fully realized strategic analysis report. Upon purchase, download the complete, ready-to-use matrix. Edit, present, or integrate it immediately into your work. No hidden content, just the finalized BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eBCG Matrix Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTandem Diabetes Care's product portfolio, as seen through a BCG Matrix lens, reveals intriguing dynamics. Some innovations likely shine as Stars, driving growth. Others may be Cash Cows, providing steady revenue. This preliminary view offers a glimpse into their strategic landscape. Uncover which products are Dogs, and which are Question Marks needing careful attention. Purchase the full BCG Matrix for a complete, data-driven strategic evaluation. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003et:slim X2 Insulin Pump\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe t:slim X2 insulin pump is a Star for Tandem Diabetes Care, given its strong market position and high growth potential. As Tandem's primary product, it benefits from the increasing adoption of AID systems. In 2024, Tandem reported a 20% increase in pump shipments, highlighting its market success. The integration with Control-IQ and CGM systems, like Dexcom G7, drives customer satisfaction and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTandem Mobi System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTandem Mobi, the world's smallest durable automated insulin delivery system, is a standout innovation. Its compact design and app control boost user convenience, potentially capturing market share. The launch of Tandem Mobi expands Tandem's offerings; in Q3 2023, Tandem reported $217.4 million in revenue, reflecting market growth. This positions Mobi as a potential \"Star\" in their BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eControl-IQ Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eControl-IQ technology, a key element of Tandem Diabetes Care, significantly boosts its market position. This technology, including Control-IQ+, is pivotal for improving glycemic control. Its recent FDA clearance for type 2 diabetes patients expands its reach. In 2024, Tandem reported strong sales, driven by its innovative technology, with a market capitalization exceeding $3 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Type 2 Diabetes Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTandem Diabetes Care's foray into the Type 2 diabetes market represents a strategic growth initiative. FDA clearance for Control-IQ+ broadens its U.S. market access. This move is expected to boost long-term growth through pilot launches. The company aims to capitalize on this expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eControl-IQ+ for Type 2 diabetes received FDA clearance in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAddressable market more than doubled in the U.S. with this expansion.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePilot launch activities targeting high insulin-prescribing providers are underway.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTandem Diabetes Care views international markets as key to future growth. Management anticipates greater expansion in international sales compared to the U.S. market in 2025. The company's focus in 2024 includes developing its international sales segment. This strategic shift aims to capitalize on global opportunities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eInternational sales are a high priority for Tandem in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company projects stronger growth internationally in 2025.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTandem is investing in its global sales infrastructure.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTandem's Rise: Pumps, Tech, and a $3B+ Market Cap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTandem's Stars, like t:slim X2 and Mobi, show strong growth. In 2024, pump shipments rose 20%, signaling market success. Control-IQ tech and international expansion boost their potential. Tandem's market cap exceeded $3B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eMarket Position\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003et:slim X2\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTandem Mobi\u003c\/td\u003e\n\u003ctd\u003eEmerging\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eControl-IQ\u003c\/td\u003e\n\u003ctd\u003eKey Feature\u003c\/td\u003e\n\u003ctd\u003eGrowing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003et:slim X2 Consumables (Infusion Sets, Cartridges)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe t:slim X2's infusion sets and cartridges are a reliable revenue source for Tandem. These consumables are vital for pump function, driving consistent sales. In 2024, recurring revenue from consumables accounted for a significant portion of Tandem's income. Ensuring product quality and availability is key to this \"cash cow.\"\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships with CGM Companies (Dexcom, Abbott)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTandem Diabetes Care's partnerships with CGM leaders Dexcom and Abbott are crucial. These collaborations enable smooth integration of CGM data, improving user experience. In 2024, Dexcom's revenue grew significantly, mirroring the importance of these integrations. Expanding these partnerships is key for sustained growth. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting Customer Base (Recurring Pump Replacements)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTandem Diabetes Care benefits from a solid customer base dependent on its products. Recurring revenue stems from pump replacements and upgrades for existing users. Innovation in features drives customer upgrades, ensuring consistent cash flow. In 2024, Tandem's revenue reached approximately $889.6 million, reflecting the importance of its customer base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTandem Choice Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Tandem Choice Program, available from September 2022 until the close of 2024, enabled t:slim X2 users to acquire the Tandem Mobi. This initiative boosted sales and supported customer migration to the newer device. The program's financial outcomes were reported under both GAAP and non-GAAP standards. It was a strategic move to enhance market penetration. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eProgram duration: September 2022 - December 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePurpose: Facilitated t:slim X2 users' transition to Tandem Mobi.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eImpact: Generated incremental sales.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReporting: Financial results provided on GAAP and non-GAAP bases.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Sales Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTandem Diabetes Care's move into pharmacy sales, particularly with the Mobi model, is a strategic shift. Launching a multi-channel strategy in the U.S., where around 20% of covered lives have pharmacy rebate deals, could boost sales. Selling insulin pumps via pharmacies from 2025 might accelerate sales growth. This approach aims to broaden accessibility and market reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003ePharmacy sales could improve market penetration.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRebate agreements may increase sales volume.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe Mobi launch is key.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e2025 sales will show the real impact.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTandem's 2024: Revenue Soars to $889.6M!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTandem's cash cows are the t:slim X2's consumables, ensuring reliable revenue. Strategic partnerships with Dexcom and Abbott also contribute to consistent cash flow. Customer base and the Tandem Choice Program boosted sales in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAspect\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003e2024 Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eFrom consumables, partnerships, and customer base.\u003c\/td\u003e\n\u003ctd\u003e$889.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Base\u003c\/td\u003e\n\u003ctd\u003eRecurring revenue from upgrades.\u003c\/td\u003e\n\u003ctd\u003eSignificant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Programs\u003c\/td\u003e\n\u003ctd\u003eTandem Choice Program\u003c\/td\u003e\n\u003ctd\u003eEnded December 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder Generation Insulin Pumps (Pre-t:slim X2)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder insulin pumps, like those predating the t:slim X2, fit the \"Dogs\" category. These older models likely have declining sales. Tandem Diabetes Care should prioritize customer upgrades to newer, revenue-generating products. In 2024, Tandem's focus is on innovative pumps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimas Vibe (Acquired from J\u0026amp;J)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTandem Diabetes Care acquired Animas Vibe from J\u0026amp;J in 2017. The pump is now a \"dog\" due to its age and lack of advanced features. Tandem should discontinue support and transition users. In Q3 2023, Tandem reported $218.3M in revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProducts Lacking CGM Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsulin pumps lacking CGM integration are \"dogs\" in Tandem's portfolio. CGM integration is crucial; pumps without it are less appealing. In Q3 2023, Tandem's sales were $210.8 million, yet non-integrated pumps likely lag. Focus should be on CGM-integrated models, phasing out outdated tech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Feature Infusion Sets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInfusion sets with limited features from Tandem Diabetes Care, or those not compatible with newer pump models, fall into the \"Dogs\" quadrant of the BCG matrix. These sets likely generate less revenue and could be candidates for discontinuation. Tandem should prioritize advanced infusion sets to improve user experience and compatibility. In 2024, Tandem reported a 24% increase in pump shipments, suggesting a shift towards newer products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eRevenue from older infusion sets is likely declining.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on advanced sets aligns with growth strategies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCompatibility with newer pumps is crucial.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued Programs (e.g., Tandem Device Updater for Legacy Devices)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiscontinued programs like the Tandem Device Updater for older devices can be classified as dogs. These programs still need upkeep, but they don't bring in much money. Tandem should shift its resources to new, profitable ventures instead. Focusing on these dogs can drain resources from growth areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eTandem's 2023 revenue was about $800 million, showing the importance of focusing on high-growth products.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMaintaining outdated programs can lead to increased costs without boosting revenue.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, the company is expected to increase revenue.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTandem's Strategy: Ditching the Dogs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e“Dogs” in Tandem's portfolio are products or services with declining sales and low market share. These include older insulin pumps and outdated infusion sets. Tandem should phase out these offerings to focus on growth areas.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eExamples\u003c\/th\u003e\n\u003cth\u003eStrategic Action\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDogs\u003c\/td\u003e\n\u003ctd\u003eOlder Pumps, Non-integrated pumps, outdated infusion sets\u003c\/td\u003e\n\u003ctd\u003eDiscontinue\/Phase Out\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Impact\u003c\/td\u003e\n\u003ctd\u003eReduced revenue, increased costs for maintenance\u003c\/td\u003e\n\u003ctd\u003eFocus on high-growth areas; 2023 Revenue around $800M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Outlook\u003c\/td\u003e\n\u003ctd\u003eEmphasis on innovative product development\u003c\/td\u003e\n\u003ctd\u003eExpected revenue increase, shift to newer products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSigi Patch Pump\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSigi, Tandem's rechargeable patch pump, is in development, targeting the expanding patch pump market. This segment is expected to grow, presenting a significant opportunity. Bringing Sigi to market demands substantial investment, alongside advancements in infusion technology and algorithms. Tandem's focus is on achieving fully closed-loop technology with its future products. In 2024, the patch pump market was valued at approximately $1.2 billion, showcasing its potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFully Automated Closed-Loop Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTandem's focus on fully automated closed-loop systems is a promising venture. These systems could dramatically improve diabetes management by automating insulin delivery based on continuous glucose monitoring, representing a growth opportunity. The company's investment in this area is significant, with a multi-year collaboration with the University of Virginia. The global diabetes devices market was valued at $16.6 billion in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration with Abbott's CGM System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe integration of Tandem Mobi with Abbott's CGM, slated for 2025, positions it as a question mark. This move could attract users favoring Abbott's tech. In 2024, Tandem's revenue was $851.5 million. Expanding globally with Mobi is also a key strategy. This integration and expansion are vital for growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtended Wear Infusion Sets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExtended wear infusion sets represent a promising area for Tandem Diabetes Care, potentially enhancing user experience and reducing the burden of frequent set changes. These sets, designed to last longer than standard options, align with Tandem's focus on innovation, alongside developments like the Sigi patch pump and advanced algorithms. However, ensuring the safety and effectiveness of extended wear sets requires substantial research and development investment. As of 2024, Tandem's commitment to closed-loop technology includes these advancements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eExtended wear infusion sets aim to reduce the frequency of set changes for users.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTandem Diabetes Care is investing in research and development for these sets.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe development aligns with their goals for closed-loop technology.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe Sigi patch pump is another area of innovation.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Algorithm Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTandem Diabetes Care is actively involved in developing new algorithms to enhance its automated insulin delivery systems. These advancements aim to boost the accuracy and efficiency of insulin delivery, ultimately improving patient outcomes. The company's focus is on automation, personalization, and simplification to create a better user experience. However, developing and validating these algorithms requires substantial investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eTandem's R\u0026amp;D expenses in 2023 were $206.2 million, reflecting its commitment to innovation.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company plans to continue investing in algorithm development to stay competitive.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eKey goals include improving therapeutic outcomes and simplifying the user experience.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTandem Mobi: A $851.5M Question?\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTandem Mobi with Abbott CGM is a question mark, leveraging Abbott's tech. Tandem's 2024 revenue was $851.5 million, aiming for global expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAspect\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eFinancials (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003eTandem Mobi with Abbott's CGM\u003c\/td\u003e\n\u003ctd\u003eRevenue: $851.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategy\u003c\/td\u003e\n\u003ctd\u003eIntegration and Global Expansion\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D expenses in 2023: $206.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Position\u003c\/td\u003e\n\u003ctd\u003ePotential for growth with Abbott users\u003c\/td\u003e\n\u003ctd\u003eDiabetes devices market: $16.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003eBCG Matrix \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eOur Tandem BCG Matrix leverages market data, company financials, industry reports, and expert insights for data-driven strategic guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070275629440,"sku":"tandemdiabetes-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/tandemdiabetes-bcg-matrix.png?v=1749416110","url":"https:\/\/swotanalysistemplates.com\/products\/tandemdiabetes-bcg-matrix","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}